Who are Evogene Ltd.'s investors?

Evogene Ltd.'s investors include Alpha Capital, ARK Investment Management, Team8.

How much funding has Evogene Ltd. raised?

Evogene Ltd. has disclosed $3.4M raised across 1 of its 2 known rounds.

Where is Evogene Ltd. headquartered?

Evogene Ltd. is headquartered in Rehovot, IL.

Evogene Ltd.

NASDAQ: EVGN

Rehovot, IL · Israel corporation · 3 known investors

Evogene applies computational chemistry and generative AI to design small molecules for commercial product development in the pharmaceutical and agricultural chemical industries. Its ChemPass AI engine generates and optimizes molecules across multiple parameters to support drug discovery and ag-chemical product development.

AgTech AI & Machine Learning Biotech

Founders & leadership

Nir NimrodiNamed on SEC filing

Sarit Firon inChairperson of the BoardManaging Partner at Team8

Yaron EldadChief Financial Officer

Eyal RonenExecutive Vice President of Business Development

Dan FalkNamed on SEC filing

Sassi MasliahVice President Corporate Development

Oded ShoseyovNamed on SEC filing

Adrian PercyNamed on SEC filing

Ofer HavivPresident and Chief Executive Officer

Leon Y. RecanatiNamed on SEC filing

Mark KapelChief Technology Officer

Investors · 3

Alpha CapitalreportedAustin

ARK Investment ManagementreportedSt. Petersburg

Team8reportedNew York · $3M – $60M

Reported raises · per SEC filings

Form D private placements

$3.4M disclosed across 1 of 2 rounds · 2024–2026

▶$3.4MraisedFeb 2026 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Nir NimrodiDirector
Sarit FironDirector
Dan FalkDirector
Gabi TarcicExecutive Officer
Leon Yehuda RecanatiDirector
Ofer HavivExecutive Officer, Director
Ilia ZhidkovExecutive Officer
Adrian PercyDirector
Yaron EldadExecutive Officer

Offering amount: $3.4M
Amount sold: $3.4M
Sales commissions: $236.9K
Placement agents: A.G.P./Alliance Global Partners
First sale: Feb 2026
Incorporated: Corporation, Israel
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$12MofferedSep 2024 · 1 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Nir NimrodiDirector
Sarit FironDirector
Yaron EldadExecutive Officer
Eyal RonenExecutive Officer
Dan FalkDirector
Sassi MasliahExecutive Officer
Oded ShoseyovDirector
Adrian PercyDirector
Ofer HavivExecutive Officer
Leon Y. RecanatiDirector
Mark KapelExecutive Officer

Offering amount: $12M
Sales commissions: $385K
Placement agents: A.G.P./Alliance Global Partners
First sale: Aug 2024
Incorporated: Corporation, Israel
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

ISS and Glass Lewis Back Evogene’s Board Nominees Ahead of Shareholder Vote — Evogene Ltd. | BriefGlancebriefglance.com · Aug 2026

Evogene Ltd. Q2 2026 Earnings Call Summaryfinance.yahoo.com · Aug 2026

Evogene (EVGN) Raises $10 Million In Equity Led Investment From ARK And Alpha Capitalpulse2.com · Sep 2020

Frequently asked questions

What does Evogene Ltd. do?: Evogene applies computational chemistry and generative AI to design small molecules for commercial product development in the pharmaceutical and agricultural chemical industries. Its ChemPass AI engine generates and optimizes molecules across multiple parameters to support drug discovery and ag-chemical product development.
Who are Evogene Ltd.'s investors?: Evogene Ltd.'s investors include Alpha Capital, ARK Investment Management, Team8.
How much funding has Evogene Ltd. raised?: Evogene Ltd. has disclosed $3.4M raised across 1 of its 2 known rounds.
Where is Evogene Ltd. headquartered?: Evogene Ltd. is headquartered in Rehovot, IL.